Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAOIB and Antioxidant for Early Dementia
NCT06467539Phase 2Recruiting
- Sponsor
- Chang Gung Memorial Hospital
- Start
- Jun 2024
- Primary completion
- May 2027
- Countries
- 1
01
Overview
Phase 2, randomised trial in Alzheimer's disease (AD) and Mild Cognitive Impairment (MCI) (2 arms), sponsored by Chang Gung Memorial Hospital. Primary endpoint: Alzheimer's Disease Assessment Scale - Cognitive Subscale at 24 weeks. Started Jun 2024; status: recruiting.
02
Conditions
Alzheimer's disease (AD)Mild Cognitive Impairment (MCI)
Beyond the preview
Go deeper on NCT06467539.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06467539.